KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Preferred Stock Liabilities (2017 - 2018)

Twist Bioscience (TWST) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $290.5 million as the latest value for Q3 2018.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $290.5 million in Q3 2018 year-over-year; TTM through Sep 2018 was $290.5 million, a N/A change, with the full-year FY2018 number at $290.5 million, up 127.18% from a year prior.
  • Preferred Stock Liabilities was $290.5 million for Q3 2018 at Twist Bioscience, up from $36.7 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $290.5 million in Q3 2018 to a low of $25.9 million in Q4 2017.